Amgen Inc. (NASDAQ:AMGN) Shares Purchased by West Paces Advisors Inc.

West Paces Advisors Inc. boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 41.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,819 shares of the medical research company’s stock after buying an additional 534 shares during the quarter. West Paces Advisors Inc.’s holdings in Amgen were worth $524,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of AMGN. Marino Stram & Associates LLC lifted its position in shares of Amgen by 0.7% in the fourth quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock valued at $1,332,000 after acquiring an additional 34 shares in the last quarter. DGS Capital Management LLC raised its stake in Amgen by 1.7% in the 4th quarter. DGS Capital Management LLC now owns 3,291 shares of the medical research company’s stock valued at $948,000 after purchasing an additional 55 shares during the last quarter. Imprint Wealth LLC lifted its holdings in Amgen by 41.8% in the 4th quarter. Imprint Wealth LLC now owns 1,411 shares of the medical research company’s stock valued at $416,000 after purchasing an additional 416 shares in the last quarter. Grant GrossMendelsohn LLC acquired a new stake in Amgen during the 4th quarter worth $214,000. Finally, Hamilton Point Investment Advisors LLC grew its holdings in shares of Amgen by 1.5% during the fourth quarter. Hamilton Point Investment Advisors LLC now owns 35,244 shares of the medical research company’s stock worth $10,151,000 after buying an additional 526 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research reports. The Goldman Sachs Group raised their price target on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Royal Bank of Canada restated an “outperform” rating and set a $329.00 target price on shares of Amgen in a report on Wednesday, April 3rd. Daiwa Capital Markets upgraded Amgen from a “neutral” rating to a “buy” rating and upped their price target for the company from $264.00 to $320.00 in a research report on Thursday, December 21st. UBS Group reduced their price objective on Amgen from $315.00 to $314.00 and set a “neutral” rating on the stock in a research report on Monday, January 29th. Finally, BMO Capital Markets raised Amgen from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $286.00 to $326.00 in a research note on Tuesday, December 19th. Ten research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $295.30.

Amgen Trading Up 0.0 %

NASDAQ:AMGN traded up $0.13 on Tuesday, hitting $265.64. 2,011,346 shares of the stock were exchanged, compared to its average volume of 2,871,636. The stock has a fifty day moving average of $279.63 and a 200-day moving average of $281.52. The stock has a market cap of $142.36 billion, a PE ratio of 21.26, a PEG ratio of 2.53 and a beta of 0.58. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company’s revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.09 EPS. As a group, equities analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.39%. Amgen’s payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.